Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cancer
NCT07622550Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, serplulimab in colorectal cancer (CRC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
fruquintinibserplulimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07622550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622550.